Project Grant R50CA318287
Award Date 8/6/26
Completion Date 7/31/31
Dollars Obligated $197K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
- The National Cancer Institute awarded Emory University $602,170 on June 2, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop biomimetic migrating nanoparticles targeting tumor stroma and neural invasion in pancreatic cancer. The recipient is developing a tumor cell mimetic hyaluronic acid nanoparticle drug delivery platform conjugated with a recombinant atfmmp14 ligand containing the amino-terminal fragment of urokinase plasminogen activator and an MMP14...
- The National Cancer Institute awarded Emory University $639,077 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop rapid quantitative amide proton transfer-weighted (APTW) magnetic resonance imaging for brain tumor characterization at 3 Tesla field strength. The work addresses clinical challenges in chemical exchange saturation transfer (CEST) MRI by refining the quasi-steady-state (QUASS) algorithm to reconstruct equilibrium CEST signals...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $181,610 on September 1, 2026, to develop and deploy computational methods for creating novel immunotherapies targeting neuroblastoma in children under the Cancer Treatment Research program (CFDA 93.395). The funded work centers on bioinformatics pipeline development and analysis of proteogenomic data to identify new immunotherapeutic targets for pediatric cancer. Under the leadership of Dr. John Maris and...
- The National Cancer Institute awarded Emory University $2,858,084 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to design and test a mobile application that re-engages young adult survivors of childhood cancer in risk-based surveillance care after their transition from pediatric to adult healthcare settings. The project, titled "Using SurvivorLink to Re-Engage Adults in Cancer Care After Transition" (SurvivorLink RE-ACCT), addresses the...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded $457,683 to The Children's Hospital of Philadelphia on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and optimize a macromolecular prodrug-based delivery strategy for the topoisomerase I inhibitor SN22 designed to overcome tumor defense mechanisms and suppress high-risk neuroblastoma, the most common and deadly solid tumor of childhood. The project targets...
- The National Cancer Institute awarded Emory University $100,228 under the Cancer Research Manpower program (CFDA 93.398) on December 1, 2026, to support research training in biomedical careers relevant to the National Cancer Program. The award funds investigation of PYCR phosphorylation in chemoimmunotherapy resistance, specifically examining how fibroblast growth factor receptor 1 (FGFR1) phosphorylates proline cycle regulatory enzymes (PYCR1 and PYCR2) and confers resistance to combined...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $721,653 on June 5, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate protein O-mannosylation as a therapeutic vulnerability in KIAA1549-BRAF-driven pediatric low-grade glioma. The research program combines molecular mechanistic studies with in vivo mouse models to validate whether O-mannosylation of the KIAA1549 fusion protein is necessary for gliomagenesis and to evaluate POMT complex...
- The Food and Drug Administration awarded Research Institute at Nationwide Children's Hospital $3.218 million on September 25, 2025, under the Food and Drug Administration Research program (CFDA 93.103) to conduct a Phase II, multi-arm, molecularly-guided umbrella trial for children and young adults with high-grade glioma, including diffuse intrinsic pontine glioma (DIPG). The trial addresses treatment outcomes for pediatric, adolescent, and young adult patients with aggressive brain and spinal...
- The National Cancer Institute awarded ST Jude Children's Research Hospital Inc. $737,023 under the Cancer Treatment Research program (CFDA 93.395) on July 23, 2026, to develop and evaluate CD19-CAR T cell therapy combined with TCR alpha/beta–depleted haploidentical hematopoietic cell transplantation for pediatric patients with relapsed or refractory CD19+ acute lymphoblastic leukemia and lymphoma. The research aims to minimize relapse risk and graft-versus-host disease while eliminating total...
- The National Cancer Institute awarded Emory University $100,228 under the Cancer Research Manpower program (CFDA 93.398) on December 1, 2026, to develop a high-throughput force assay for screening chimeric antigen receptor T cell (CAR T) function. The research introduces a novel assay using DNA-based force probes combined with CAS12A enzymatic amplification to quantify piconewton-level forces exerted by CAR T cells via standard plate reader formats. Work includes investigation of how...